AstraZeneca’s Combination Therapy Shows Significant Efficacy in Phase III Trial Cambridge, UK- On Monday, AstraZeneca’s combination of Truqap (capivasertib) with Faslodex (fulvestrant) received a recommendation for approval from the Committee…
Consistent Growth and Expanded Market Reach Highlight Early Success; Final Dividend Announced London, UK— This Thursday, Hikma Pharmaceuticals PLC provided a trading update in advance of its Annual General Meeting,…
German Chancellor Olaf Scholz and Merck Celebrate Laying for Advanced Research Facility Darmstadt, Germany — This Thursday, Merck announced an investment of over €300 million in the construction of a…